Le Lézard
Classified in: Health
Subjects: TDS, FEA

Elekta MR-linac Featured in Record-breaking 42 Abstracts at ESTRO 37


BARCELONA, April 23, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that its transformative MR-linac system is featured in 42 abstracts at the European Society for Radiotherapy and Oncology (ESTRO) 37th Annual Conference, taking place April 20 ? 24 in Barcelona. Founding members of the Elekta MR-linac Consortium are presenting 36 abstracts and new collaborators from an ever-growing number of world-class cancer centers are presenting six abstracts. Elekta MR-linac is groundbreaking because it overcomes the technical barriers that have hindered the integration of radiation therapy with real-time high-field 1.5 Tesla (T) MR imaging. It is the only system to truly unlock the imaging capabilities of MR/RT, enabling clinicians to see what they treat in real time and offer each patient truly personalized therapy.

"For decades radiation oncologists have been challenged by the inability to see what we treat in real time, and the expansive body of MR-linac data presented at ESTRO 37 makes it clear that the dawn of a wholly new approach to radiation therapy is on the horizon," said Ananya Choudhury, MA, PhD, MRCP, FRCR, The Christie NHS Foundation Trust, UK. "These data demonstrate that MR-linac has the potential to transform how cancer is treated by allowing more effective tumor targeting, providing better protection for healthy tissue and organs at risk, reducing side effects and enabling real-time adaptation of treatment plans. The ability to see what we treat has the potential to fundamentally change the way we currently treat patients and enable the radiation oncology community to dramatically improve health outcomes."  

The Elekta MR-linac Consortium is a collaborative industrial-academic partnership that Elekta founded with seven centers and its technology partner, Philips, in 2012 to provide an evidence-based introduction of Elekta MR-linac to the medical community, and to support the advancement of the technology.

Key findings presented at ESTRO 37 include:

"The 42 abstracts presented at this conference is continued evidence of the intensity of the work of the Elekta MR-linac Consortium which has resulted in 125 scientific papers on Elekta's MR-linac, more than any other MR-guided radiation delivery system," said Elekta CEO, Richard Hausmann. "With this expert community, Elekta has achieved a technical tour-de-force by working with those on the front line of cancer therapy to innovative next-generation technologies that address unmet needs. We recognize the critical role that the consortium members played in making the ability to see what is treated in real-time a reality, and in developing the clinical protocols and processes that will enable MR/RT and transform patient care as we gear up for pending market introduction."  

Additional information about Elekta MR-linac can be found at www.elekta.com/mrrt .

Elekta MR-linac is a work in progress and not available for sale or distribution.

For further information, please contact:

Oskar Bosson
Global EVP Corporate Communications and Investor Relations
Tel: +46-70-410-7180
e-mail: [email protected] 
Time zone: CET: Central European Time

Michelle Joiner
Director, Global Media Relations
Tel: +1-770-670-2447
e-mail: [email protected]
Time zone: ET: Eastern Time

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/elekta/r/elekta-mr-linac-featured-in-record-breaking-42-abstracts-at-estro-37,c2502119

The following files are available for download:

http://mb.cision.com/Main/35/2502119/826970.pdf

PDF


These press releases may also interest you

at 16:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As...

at 16:10
ENDRA Life Sciences Inc. , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Highlights from the fourth quarter of 2023...

at 16:08
Today, MPOWERHealth, a pioneer in the field of intraoperative neuromonitoring (IONM), announced the strategic acquisition of Assure Neuromonitoring's operations in pivotal markets, marking a significant step in expanding its best-in-class...

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....



News published on and distributed by: